Genentech licenses Hanmi's obesity candidate in a $2.3 billion deal

Genentech, part of Roche, has agreed to license an obesity drug candidate from South Korea's Hanmi Pharmaceutical in a deal valued at up to $2.3 billion. The candidate is based on a hormone called UCN2, a mechanism separate from the GLP-1 pathway used by semaglutide (sold as Ozempic, Wegovy, and Rybelsus) and tirzepatide (sold as Mounjaro and Zepbound). The agreement, announced August 25, 2026, is one more sign that large drugmakers are willing to pay heavily for obesity assets that do not rely on GLP-1 biology.

Detailed terms of the Genentech-Hanmi agreement, including upfront payment size, milestone structure, and expected timelines for clinical trials, are not available in the sourcing reviewed for this story. What is known is the total deal value and that it fits a pattern of heavy dealmaking around obesity drugs that continued through 2026.

That pattern comes against a backdrop of fast-moving competition in the GLP-1 market itself. Novo Nordisk launched an oral version of Wegovy in the United States in January 2026, making it the first oral GLP-1 receptor agonist available for weight management in the country ^[1]. The move was widely seen as an attempt to get ahead of Eli Lilly's orforglipron, sold under the brand name Foundayo, while regulators were still reviewing that rival oral drug ^[1]. Novo Nordisk executives described the launch as an important opportunity to shape the market before that competition arrived ^[1].

The Hanmi deal signals that competition in obesity treatment is no longer limited to a race between GLP-1 drugmakers. Companies are now placing large bets on entirely different biological mechanisms, hoping to find treatments that might work for patients who don't respond well to GLP-1 drugs, have trouble tolerating their side effects, or are looking for options as the obesity drug market keeps expanding.

Why it matters for patients

For patients currently using or considering semaglutide or tirzepatide products, this deal does not change anything about those drugs' availability, price, or approved uses right now. UCN2-based treatments are not GLP-1 medicines, and Hanmi's candidate is not yet approved by the Food and Drug Administration for any use.

What this deal does suggest is that the pipeline of future obesity treatments may include drugs that work through different mechanisms than the injectable and oral GLP-1 drugs already on the market. If a UCN2-based drug eventually reaches approval, it could someday give patients and doctors another category of treatment to weigh, alongside existing options and Lilly's oral orforglipron pill, Foundayo. But that possibility is likely years away, and nothing in the available sourcing indicates when or whether Hanmi's candidate will complete clinical trials or reach regulators.

In the meantime, the intensity of dealmaking around obesity treatments — reflected both in this $2.3 billion licensing agreement and in Novo Nordisk's move to launch an oral Wegovy pill ahead of Lilly's rival product ^[1] — points to a market where companies expect strong demand and are racing to secure new mechanisms and formulations. That competitive pressure could eventually affect pricing, insurance coverage decisions, and the range of choices available to patients, though none of those effects have yet been reported in connection with this specific deal.

What happens next

Specific development timelines for Hanmi's UCN2 candidate under Genentech are not detailed in current sourcing. Separately, Lilly's oral orforglipron pill, marketed as Foundayo, remains under regulatory review in the United States following Novo Nordisk's earlier launch of oral Wegovy in January 2026 ^[1]. Further details on both fronts are not yet known and will depend on future company and regulatory announcements.